Bone Marrow News and Research RSS Feed - Bone Marrow News and Research

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.
Stem cell treatment for osteoarthritis of the knee may help rebuild lost cartilage

Stem cell treatment for osteoarthritis of the knee may help rebuild lost cartilage

Recent studies employing adult stem cells obtained from bone marrow and fat have been used in patients suffering from osteoarthritis of the knee. Results have indicated not only symptomatic improvement but also suggest that cartilage healing and regeneration may be taking place. [More]
Researchers identify new role for VEGFA that may help target metastatic neuroblastoma

Researchers identify new role for VEGFA that may help target metastatic neuroblastoma

Healthy bone is continuously involved in a dynamic process that includes bone deposition and bone resorption. [More]
MRD-directed therapy helps boost survival of young leukemia patients

MRD-directed therapy helps boost survival of young leukemia patients

Measuring the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy should help boost survival of young leukemia patients by better matching patients with the right intensity of chemotherapy. St. Jude Children's Research Hospital investigators led the research, which appears in the March 20 edition of the journal Lancet Oncology. [More]
Royal Free London NHS Foundation Trust deploys OpenText to manage patient medical care records

Royal Free London NHS Foundation Trust deploys OpenText to manage patient medical care records

OpenText, the global leader in Enterprise Information Management (EIM), today announced that the Royal Free London NHS Foundation Trust has implemented OpenText Content Suite to store and manage digitised copies of patient medical care records. [More]
Researchers successfully generate cells of immune system to target, destroy cancer cells

Researchers successfully generate cells of immune system to target, destroy cancer cells

Researchers at the Max Delbrück Center for Molecular Medicine Berlin-Buch and Charité - Universitätsmedizin Berlin, Campus Berlin-Buch, have succeeded in generating cells of the immune system to specifically target and destroy cancer cells. [More]
Vitamin D plays major role in preventing diabetes and atherosclerosis

Vitamin D plays major role in preventing diabetes and atherosclerosis

In recent years, a deficiency of vitamin D has been linked to type 2 diabetes and heart disease, two illnesses that commonly occur together and are the most common cause of illness and death in Western countries. Both disorders are rooted in chronic inflammation, which leads to insulin resistance and the buildup of artery-clogging plaque. [More]
New bone marrow transplant unit launched in Bangalore, India

New bone marrow transplant unit launched in Bangalore, India

A bone marrow transplant can mean the difference between life and death for people with blood cancers and related disorders. But many patients in India can't afford the high treatment costs, and for them a transplant is not an option. This is changing thanks to a newly launched bone marrow transplant unit at M.S. Ramaiah Medical College in Bangalore. [More]
CUMC researchers identify mechanism of kidney transplant tolerance

CUMC researchers identify mechanism of kidney transplant tolerance

Columbia University Medical Center researchers have pinpointed the immune system mechanism that allows a kidney transplant to be accepted without lifelong immunosuppressive drugs, a significant step toward reducing or eliminating the need for costly and potentially toxic immunosuppressant drugs and improving long-term transplant success. [More]
Vaxil Bio's ImMucin receives EMA orphan drug designation for treatment of Multiple Myeloma

Vaxil Bio's ImMucin receives EMA orphan drug designation for treatment of Multiple Myeloma

Vaxil Bio, a leading developer of immunotherapeutic products to treat cancer and infectious diseases, reports today that its lead drug candidate, ImMucin has received orphan drug designation from the European Medicines Agency of the European Commission for the treatment of Multiple Myeloma (MM), a blood cancer. [More]
Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

CTI BioPharma Corp. today announced that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor currently in Phase 3 development in the PERSIST program. [More]
New immunotoxin found to be safe, effective in patients with B-cell malignancies

New immunotoxin found to be safe, effective in patients with B-cell malignancies

Almost all patients with a group of blood cancers called B-cell malignancies have two prominent "fingerprints" on the surface of leukemia and lymphoma cancers, called CD22 and CD19, Vallera explained. [More]
Finding could lead to more effective, less invasive treatment for 'bubble boy' disease

Finding could lead to more effective, less invasive treatment for 'bubble boy' disease

For infants with severe combined immunodeficiency (SCID), something as simple as a common cold or ear infection can be fatal. Born with an incomplete immune system, kids who have SCID--also known as "bubble boy" or "bubble baby" disease--can't fight off even the mildest of germs. [More]
Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug conjugates

Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug conjugates

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs). [More]
Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

PharmaEssentia (Taipei, Taiwan) and AOP Orphan (Vienna, Austria) announce the completion of recruitment for the Phase III trial PROUD-PV to support global marketing of P1101 (Ropeginterferon alfa-2b), a novel, long-acting, mono-pegylated interferon for the first line treatment of polycythemia vera. [More]
New stem cell treatment reverses disability in certain MS patients

New stem cell treatment reverses disability in certain MS patients

A PIONEERING new stem cell treatment ‘rebooting’ the immune system in some multiple sclerosis sufferers is being hailed as an encouraging step forward in the treatment of the disease in sufferers who fail to respond to standard therapies. [More]
United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. [More]
Researchers identify new class of drugs that slows aging process

Researchers identify new class of drugs that slows aging process

A research team from The Scripps Research Institute, Mayo Clinic and other institutions has identified a new class of drugs that in animal models dramatically slows the aging process—alleviating symptoms of frailty, improving cardiac function and extending a healthy lifespan. [More]
Researchers use stem cells from sickle cell disease patients to grow mature red blood cells

Researchers use stem cells from sickle cell disease patients to grow mature red blood cells

Researchers at Johns Hopkins have successfully corrected a genetic error in stem cells from patients with sickle cell disease, and then used those cells to grow mature red blood cells, they report. The study represents an important step toward more effectively treating certain patients with sickle cell disease who need frequent blood transfusions and currently have few options. [More]
18F-fluoride PET/MR imaging could diagnose cause of foot pain better than other methods

18F-fluoride PET/MR imaging could diagnose cause of foot pain better than other methods

A single scan could diagnose the cause of foot pain better and with less radiation exposure to the patient than other methods, according to a study in the March 2015 issue of The Journal of Nuclear Medicine. [More]
Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

CTI BioPharma Corp. and Baxter International Inc. today announced positive top-line results for the primary endpoint from PERSIST-1, the randomized, controlled Phase 3 registration clinical trial examining pacritinib, a next generation oral JAK2/FLT3 multikinase inhibitor, for the treatment of patients with primary or secondary myelofibrosis. [More]
Advertisement
Advertisement